Hughes Network Systems LLC (HUGHES) is a global leader in broadband satellite technology and services for home and office. Its flagship high-speed satellite Internet service is HughesNet®, the world’s largest satellite network, with over 1 million residential and business customers across North America and Brazil.

For large enterprises and governments, the company’s HughesON® managed network services provide complete connectivity solutions, employing an optimized mix of satellite and terrestrial technologies. The company’s JUPITER™ System is the world’s most widely deployed High-Throughput Satellite (HTS) platform, operating on more than 20 satellites by leading service providers, delivering a wide range of broadband enterprise, mobility and cellular backhaul applications.

To date, Hughes has shipped more than 5.5 million terminals to customers in over 100 countries, representing an approximately 50 percent market share, and its technology is powering broadband services to aircraft around the world.

With annual revenues of over $1 billion, Hughes’ headquarters are in Germantown, Md., although the company has offices in 11 countries and customers in over 100 countries.

Black & Decker has been setting the standard for home improvement products since 1910. With roots in Baltimore, Maryland, the company evolved from a small machine shop that invented the first portable electric drill to a global manufacturing and marketing powerhouse. Black & Decker’s product line now includes a broad variety of products for both commercial and residential use.

Black & Decker has been setting the standard for home improvement products since 1910. With roots in Baltimore, Maryland, the company evolved from a small machine shop that invented the first portable electric drill to a global manufacturing and marketing powerhouse. Black & Decker’s product line now includes a broad variety of products for both commercial and residential use.

MedImmune is the global biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across Oncology, Respiratory, Cardiovascular & Metabolic Diseases, and Infection and Vaccines. MedImmune is headquartered in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers, with additional sites in Cambridge, UK and Mountain View, Calif.

MedImmune’s SYNAGIS therapeutic is an FDA-approved prescription injection of antibodies that is given monthly to help protect high-risk infants from severe respiratory syncytial virus, or RSV.

RSV is a common virus that, like the flu, is seasonal and easily spread. Most children will get RSV by the age of two. RSV begins with cold-like symptoms but can spread to the lungs. For babies with certain health conditions, RSV can be very serious.

SYNAGIS is the first monoclonal antibody approved for the prevention of an infectious disease, as well as the first such drug to be safely used in children.